Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.78 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.78 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.78 |
| ▸ | MAPT | P10636 | 4/20 | 0.78 |
| ▸ | CA12 | O43570 | 3/20 | 0.78 |
| ▸ | CA4 | P22748 | 3/20 | 0.78 |
| ▸ | CA7 | P43166 | 3/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.78 |
| ▸ | TP53 | P04637 | 3/20 | 0.78 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.78 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | PKM | P14618 | 2/20 | 0.78 |
| ▸ | HPGD | P15428 | 2/20 | 0.78 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pinocembrin SCHEMBL3437711 | 0.93 | CYP19A1 (0.88) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL1333765 | 0.92 | CYP19A1 (0.81) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL29378971 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL29382523 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL29603762 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL23686074 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL30468822 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL29709569 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL19180 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Eriodictyol SCHEMBL2309591 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373471-A1 | COMBINATION FOR USE FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, CARDIOVASCULAR DISEASE AND METABOLIC SYNDROME | Meda Pharma S.p.A. (IT) | 2024-05-29 | — | — | EP | disclosed |
| CN-117813079-A | Combination for the treatment of hypercholesterolemia, hyperlipidemia, cardiovascular diseases and metabolic syndrome | 美达制药股份公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117529238-A | Flavoring composition for taste improvement | 西姆莱斯有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4161291-B1 | FLAVORING COMPOSITIONS FOR TASTE IMPROVEMENT | SYMRISE AG (DE) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023166862-A1 | BEVERAGE CONTAINING ERIOCITRIN AND JUICE | サントリーホールディングス株式会社 | 2023-09-07 | — | — | WO | disclosed |
| EP-3399959-B1 | COMPOSITION TO IMPROVE METABOLIC AND VASCULAR HEALTH AND HEALTH SPAN | THORNALLEY PAUL JOHN (GB) | 2023-05-24 | — | — | EP | disclosed |
| EP-4161291-A1 | FLAVORING COMPOSITIONS FOR TASTE IMPROVEMENT | Symrise AG (DE) | 2023-04-12 | — | — | EP | disclosed |
| US-20230068267-A1 | PLANT EXTRACT COMPOSITION FOR THE TREATMENT OF CARDIOVASCULAR AND METABOLIC DISEASES | MEDA Pharma S.p.A. (IT) | 2023-03-02 | — | — | US | disclosed |
| WO-2023017021-A1 | FLAVORING COMPOSITIONS FOR TASTE IMPROVEMENT | SYMRISE AG (DE) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016630-A1 | FLAVORING COMPOSITIONS FOR TASTE IMPROVEMENT | SYMRISE AG (DE) | 2023-02-16 | — | — | WO | disclosed |
| EP-2484773-A2 | Process for producing anthocyanins | The Research Foundation of State University of New York (US) | 2012-08-08 | — | — | EP | disclosed |
| US-7807422-B2 | set of genes which encodes for enzymes which can convert substrates belonging to the general category of phenylpropanoids and result in the production of flavanones; without the need for chemical conversion | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090239272-A1 | set of genes which encodes for enzymes which can convert substrates belonging to the general category of phenylpropanoids and result in the production of flavanones; without the need for chemical conversion | KOFFAS MATTHEOS | 2009-09-24 | — | — | US | disclosed |
| US-7338791-B2 | Introducing the set of genes into a heterologous host cell, allowing growth of the cells in a suitable medium such that the expression of the genes results in production of enzymes; culturing the cell under conditions permitting the synthesis of the flavonoid by the cells; isolating s flavonoids | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1778850-A2 | PRODUCTION OF FLAVONOIDS BY RECOMBINANT MICROORGANISMS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-05-02 | — | — | EP | disclosed |
| CN-1787834-A | One or several enzyme-containing compounds, dietetic food products and drugs produced from said compounds and the use therefor for medical purposes | MUCOS PHARMA GMBH & CO (DE) | 2006-06-14 | — | — | CN | disclosed |
| EP-1624887-A1 | ONE OR SEVERAL ENZYME-CONTAINING COMPOUNDS, DIETETIC FOOD PRODUCTS AND DRUGS PRODUCED FROM SAID COMPOUNDS AND THE USE THEREFOR FOR MEDICAL PURPOSES | MUCOS Pharma GmbH & Co. (DE) | 2006-02-15 | — | — | EP | disclosed |
| US-20060019334-A1 | Introducing the set of genes into a heterologous host cell, allowing growth of the cells in a suitable medium such that the expression of the genes results in production of enzymes; culturing the cell under conditions permitting the synthesis of the flavonoid by the cells; isolating s flavonoids | NATIONAL SCIENCE FOUNDATION | 2006-01-26 | — | — | US | disclosed |
| WO-2006010117-A2 | PRODUCTION OF FLAVONOIDS BY RECOMBINANT MICROORGANISMS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2004100981-A1 | ONE OR SEVERAL ENZYME-CONTAINING COMPOUNDS, DIETETIC FOOD PRODUCTS AND DRUGS PRODUCED FROM SAID COMPOUNDS AND THE USE THEREFOR FOR MEDICAL PURPOSES | MUCOS PHARMA GMBH & CO. (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230068267-A1 | PLANT EXTRACT COMPOSITION FOR THE TREATMENT OF CARDIOVASCULAR AND METABOLIC DISEASES | PCSK9, CHLSN, CETP | CYP19A1 992/4885CYP3A4 917/4885CYP1A1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.